About this Framework
The FDA's cybersecurity programme for medical devices (codified in the Consolidated Appropriations Act 2023, Section 3305) requires manufacturers to submit cybersecurity plans covering vulnerability monitoring, coordinated disclosure policies, software bill of materials (SBOM), design controls and post-market patching capabilities with every pre-market device submission (510(k), PMA, De Novo). The FDA also publishes sector-specific playbooks for ransomware response and medical device incident management covering connected hospital environments.
Key Control Domains
Secure Product Development Framework (SPDF)
Software Bill of Materials (SBOM)
Vulnerability Monitoring & Coordinated Disclosure
Cybersecurity Design Controls
Patch & Update Management
Post-Market Cybersecurity Surveillance
Incident Response Planning
Network Security Segmentation
Authentication & Authorisation
Who Needs This?
- Medical device manufacturers submitting 510(k) and PMA applications
- In vitro diagnostic (IVD) device manufacturers
- Healthcare delivery organisations managing connected medical devices
- Medical IoT (IoMT) platform providers and system integrators
- Clinical engineering departments managing device security
Compliance Benefits
- FDA pre-market submission compliance (legally required since October 2023)
- Reduced device recall risk from cybersecurity vulnerabilities
- Structured SBOM programme for software component transparency
- Alignment with NIST CSF and IEC 62443 for connected medical systems
Official Reference
FDA Medical Device Cybersecurity Guidance
https://www.fda.gov/medical-devices/digital-health-center-excellence/cybersecurity
Assessment Details
Share this Assessment
Share this permanent link with your team, clients or auditors.
https://grcopilot.app/frameworks/fda-medical-device-cybersecurity-assessment